220 related articles for article (PubMed ID: 2154672)
1. Studies on kinetics of [3H]beta-funaltrexamine binding to mu opioid receptor.
Liu-Chen LY; Li SX; Tallarida RJ
Mol Pharmacol; 1990 Feb; 37(2):243-50. PubMed ID: 2154672
[TBL] [Abstract][Full Text] [Related]
2. Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.
Tam SW; Liu-Chen LY
J Pharmacol Exp Ther; 1986 Nov; 239(2):351-7. PubMed ID: 3021954
[TBL] [Abstract][Full Text] [Related]
3. Covalent labeling of mu opioid binding site by [3H]beta-funaltrexamine.
Liu-Chen LY; Phillips CA
Mol Pharmacol; 1987 Sep; 32(3):321-9. PubMed ID: 2823089
[TBL] [Abstract][Full Text] [Related]
4. Interaction of beta-funaltrexamine with [3H]cycloFOXY binding in rat brain: further evidence that beta-FNA alkylates the opioid receptor complex.
Rothman RB; Bykov V; Mahboubi A; Long JB; Jiang Q; Porreca F; de Costa BR; Jacobson AE; Rice KC; Holaday JW
Synapse; 1991 Jun; 8(2):86-99. PubMed ID: 1652797
[TBL] [Abstract][Full Text] [Related]
5. Effect of intracerebroventricular beta-funaltrexamine on mu opioid receptors in the rat brain: consideration of binding condition.
Liu-Chen LY; Yang HH; Li S; Adams JU
J Pharmacol Exp Ther; 1995 Jun; 273(3):1047-56. PubMed ID: 7791074
[TBL] [Abstract][Full Text] [Related]
6. Beta-[3H]funaltrexamine-labeled mu-opioid receptors: species variations in molecular mass and glycosylation by complex-type, N-linked oligosaccharides.
Liu-Chen LY; Chen C; Phillips CA
Mol Pharmacol; 1993 Oct; 44(4):749-56. PubMed ID: 8232225
[TBL] [Abstract][Full Text] [Related]
7. Autoradiographic study of irreversible binding of [3H]beta-funaltrexamine to opioid receptors in the rat forebrain: comparison with mu and delta receptor distribution.
Liu-Chen LY; Li SX; Lewis ME
Brain Res; 1991 Mar; 544(2):235-42. PubMed ID: 1645609
[TBL] [Abstract][Full Text] [Related]
8. Kinetic studies on binding of [3H] beta-funaltrexamine ([3H] beta-FNA) to mu opioid receptors.
Liu-Chen LY; Li S; Holowecky O; Tallarida RJ
Prog Clin Biol Res; 1990; 328():57-60. PubMed ID: 2154818
[No Abstract] [Full Text] [Related]
9. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
10. Alkylation of mu opioid receptors by beta-funaltrexamine in vivo: comparison of the effects on in situ binding and heroin self-administration in rats.
Martin TJ; Dworkin SI; Smith JE
J Pharmacol Exp Ther; 1995 Mar; 272(3):1135-40. PubMed ID: 7891326
[TBL] [Abstract][Full Text] [Related]
11. beta-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence.
Rothman RB; Long JB; Bykov V; Jacobson AE; Rice KC; Holaday JW
J Pharmacol Exp Ther; 1988 Nov; 247(2):405-16. PubMed ID: 2846819
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of multiple kappa-opioid receptors by selective and nonselective ligand binding in guinea pig spinal cord: resolution of high and low affinity states of the kappa 2 receptors by a computerized model-fitting technique.
Tiberi M; Magnan J
Mol Pharmacol; 1990 May; 37(5):694-703. PubMed ID: 2160061
[TBL] [Abstract][Full Text] [Related]
13. Cross-linking of human [125I]beta-endorphin to opioid receptors in rat striatal membranes: biochemical evidence for the existence of a mu/delta opioid receptor complex.
Schoffelmeer AN; Yao YH; Gioannini TL; Hiller JM; Ofri D; Roques BP; Simon EJ
J Pharmacol Exp Ther; 1990 Apr; 253(1):419-26. PubMed ID: 2158552
[TBL] [Abstract][Full Text] [Related]
14. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
15. Effects of intracerebroventricular administration of beta-funaltrexamine on [3H]DAMGO binding to rat brain sections.
Martin TJ; Dworkin SI; Smith JE
J Pharmacol Exp Ther; 1993 Oct; 267(1):506-14. PubMed ID: 8229781
[TBL] [Abstract][Full Text] [Related]
16. Interaction of [3H]spiperone with rat striatal dopamine D-2 receptors: kinetic evidence for antagonist-induced formation of ternary complex.
Chatterjee TK; Scott CE; Vazquez DM; Bhatnagar RK
Mol Pharmacol; 1988 Apr; 33(4):402-13. PubMed ID: 3357484
[TBL] [Abstract][Full Text] [Related]
17. Opioid receptor binding characteristics of the non-equilibrium mu antagonist, beta-funaltrexamine (beta-FNA).
Ward SJ; Fries DS; Larson DL; Portoghese PS; Takemori AE
Eur J Pharmacol; 1985 Jan; 107(3):323-30. PubMed ID: 2984010
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of beta-funaltrexamine binding to wild-type and mutant mu-opioid receptors expressed in Chinese hamster ovary cells.
Spivak CE; Beglan CL
Synapse; 2004 May; 52(2):123-35. PubMed ID: 15034918
[TBL] [Abstract][Full Text] [Related]
19. beta-Funaltrexamine, a gauge for the recognition site of wildtype and mutant H297Q mu-opioid receptors.
Spivak CE; Beglan CL; Zöllner C; Surratt CK
Synapse; 2003 Jul; 49(1):55-60. PubMed ID: 12710015
[TBL] [Abstract][Full Text] [Related]
20. Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic.
De Souza EB; Schmidt WK; Kuhar MJ
J Pharmacol Exp Ther; 1988 Jan; 244(1):391-402. PubMed ID: 2826773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
